These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31545799)

  • 1. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
    Kimonis V; Surampalli A; Wencel M; Gold JA; Cowen NM
    PLoS One; 2019; 14(9):e0221615. PubMed ID: 31545799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
    Strong TV; Miller JL; McCandless SE; Gevers E; Yanovski JA; Matesevac L; Bohonowych J; Ballal S; Yen K; Hirano P; Cowen NM; Bhatnagar A
    J Neurodev Disord; 2024 Apr; 16(1):22. PubMed ID: 38671361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
    Miller JL; Gevers E; Bridges N; Yanovski JA; Salehi P; Obrynba KS; Felner EI; Bird LM; Shoemaker AH; Angulo M; Butler MG; Stevenson D; Abuzzahab J; Barrett T; Lah M; Littlejohn E; Mathew V; Cowen NM; Bhatnagar A;
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1676-1685. PubMed ID: 36639249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study.
    Miller JL; Gevers E; Bridges N; Yanovski JA; Salehi P; Obrynba KS; Felner EI; Bird LM; Shoemaker AH; Angulo M; Butler MG; Stevenson D; Goldstone AP; Wilding J; Lah M; Shaikh MG; Littlejohn E; Abuzzahab MJ; Fleischman A; Hirano P; Yen K; Cowen NM; Bhatnagar A;
    Obesity (Silver Spring); 2024 Feb; 32(2):252-261. PubMed ID: 37919617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
    Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
    PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial.
    Hollander E; Levine KG; Ferretti CJ; Freeman K; Doernberg E; Desilva N; Taylor BP
    J Psychiatr Res; 2021 May; 137():643-651. PubMed ID: 33190843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial.
    Yang A; Choi JH; Sohn YB; Eom Y; Lee J; Yoo HW; Jin DK
    Orphanet J Rare Dis; 2019 Sep; 14(1):216. PubMed ID: 31511031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
    Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.
    Dykens EM; Miller J; Angulo M; Roof E; Reidy M; Hatoum HT; Willey R; Bolton G; Korner P
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
    Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
    Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
    Höybye C
    Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.
    Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
    Endocrine; 2012 Apr; 41(2):191-9. PubMed ID: 22081257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Trials in Prader-Willi Syndrome: A Review.
    Mahmoud R; Kimonis V; Butler MG
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
    McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
    Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.
    Damen L; Grootjen LN; Juriaans AF; Donze SH; Huisman TM; Visser JA; Delhanty PJD; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2021 May; 94(5):774-785. PubMed ID: 33296519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.
    Miller JL; Tamura R; Butler MG; Kimonis V; Sulsona C; Gold JA; Driscoll DJ
    Am J Med Genet A; 2017 May; 173(5):1243-1250. PubMed ID: 28371242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels.
    Purtell L; Sze L; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
    Neuropeptides; 2011 Aug; 45(4):301-7. PubMed ID: 21722955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
    Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
    Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study.
    Miller JL; Linville TD; Dykens EM
    J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):23-9. PubMed ID: 23893676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.